The purpose of this resource is to provide tissue, cells and pathology services to all 5 research projects andcareer or research development awardees covered by this application. The plan for this Lymphoma SPOREis to combine pathology resources of the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM)and its affiliated institutions with those of The Methodist Hospital to ensure adequate numbers and timelydelivery of tissue/cell samples for the projected needs of project investigators. It will therefore co-ordinateacquisition of tissue for banking from lymphoma and CLL patients at 5 affiliated hospitals in the TexasMedical Center, by relying on tissue collection and distribution systems already in place. The capacity toobtain samples from 5 affiliated hospitals will greatly increase the number of specimens we are able toanalyze, store and distribute. The core will also provide pathology services including routine tissuepreparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays,flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. These tasksare essential to the successful completion of planned experiments in each project and will be performed byexpert pathologists and histotechnologists with substantial experience in providing core services to SPOREinvestigators. We believe the resultant Tissue Core will have the necessary laboratory space, equipment andhuman resources to handle the workload outlined for the Lymphoma SPORE. This core also containsbioinformatics support to support tissue-banking software needs for the lymphoma core and includesinvestigators with expertise in developing CDEs and experience working with the BCM Prostate SPOREs todevelop a caBIG compliant system linking biospecimen data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA126752-01
Application #
7253736
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-09-11
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$313,763
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
McClain, Kenneth L; Picarsic, Jennifer; Chakraborty, Rikhia et al. (2018) CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607-2620
Gomes-Silva, Diogo; Ramos, Carlos A (2018) Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 13:
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975

Showing the most recent 10 out of 270 publications